These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 23201857)

  • 21. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Scale-up of national antiretroviral therapy programs: progress and challenges in the Asia Pacific region.
    Srikantiah P; Ghidinelli M; Bachani D; Chasombat S; Daoni E; Mustikawati DE; Nhan do T; Pathak LR; San KO; Vun MC; Zhang F; Lo YR; Narain JP
    AIDS; 2010 Sep; 24 Suppl 3():S62-71. PubMed ID: 20926930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Out of Africa: Uganda and UNAIDS advance a bold experiment.
    Zuniga J
    J Int Assoc Physicians AIDS Care; 1999 Oct; 5(10):48-60. PubMed ID: 11366872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The obligation to provide antiretroviral treatment in HIV prevention trials.
    Lo B; Padian N; Barnes M
    AIDS; 2007 Jun; 21(10):1229-31. PubMed ID: 17545698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.
    Quentin W; König HH; Schmidt JO; Kalk A
    Trop Med Int Health; 2008 Oct; 13(10):1245-56. PubMed ID: 18721185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and acceptability of delivery of antiretroviral treatment in health centres by health officers and nurses in Ethiopia.
    Assefa Y; Kiflie A; Tekle B; Mariam DH; Laga M; Van Damme W
    J Health Serv Res Policy; 2012 Jan; 17(1):24-9. PubMed ID: 22096081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.
    Jordan MR; Bennett DE; Bertagnolio S; Gilks CF; Sutherland D
    Antivir Ther; 2008; 13 Suppl 2():15-23. PubMed ID: 18575188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Out-of-pocket costs of AIDS care in China: are free antiretroviral drugs enough?
    Moon S; Van Leemput L; Durier N; Jambert E; Dahmane A; Jie Y; Wu G; Philips M; Hu Y; Saranchuk P
    AIDS Care; 2008 Sep; 20(8):984-94. PubMed ID: 18777223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining evidence for access to and benefits from antiretroviral treatment to inform planning.
    ; Marlink R; Forsythe S; Bertozzi SM; Muirhead D; Holmes M; Sturchio J
    AIDS; 2008 Jul; 22 Suppl 1():S121-2. PubMed ID: 18664943
    [No Abstract]   [Full Text] [Related]  

  • 30. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
    Kitkungvan D; Apisarnthanarak A; Laowansiri P; Mundy LM
    HIV Med; 2008 Oct; 9(8):636-41. PubMed ID: 18643857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV in the tropics: staging in the resource-limited setting.
    Varughese JK; Rosenberg MG; Kim K
    Curr Opin Infect Dis; 2012 Oct; 25(5):477-83. PubMed ID: 22744319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is antiretroviral therapy cost-effective in South Africa?
    Braithwaite RS; Tsevat J
    PLoS Med; 2006 Jan; 3(1):e60. PubMed ID: 16435892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress of the National Pediatric Free Antiretroviral Therapy program in China.
    Zhao Y; Sun X; He Y; Tang Z; Peng G; Liu A; Qiao X; Li H; Chen Z; Dou Z; Ma Y; Liu Z; Zhang F
    AIDS Care; 2010 Oct; 22(10):1182-8. PubMed ID: 20665285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings.
    Schneider K; Puthanakit T; Kerr S; Law MG; Cooper DA; Donovan B; Phanuphak N; Sirisanthana V; Ananworanich J; Ohata J; Wilson DP
    AIDS; 2011 Jun; 25(9):1143-51. PubMed ID: 21505319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Costs and adherence to antiretroviral treatment].
    Ventura-Cerdá JM; Ayago-Flores D; Vicente-Escrig E; Mollá-Cantavella S; Alós-Almiñana M
    Farm Hosp; 2010; 34(6):284-92. PubMed ID: 20692861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [When to initiate antiretroviral therapy and what to start with?].
    Viget N; Yazdanpanah Y
    Rev Prat; 2006 May; 56(9):953-63. PubMed ID: 16775976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementing early-warning indicators of HIV drug resistance in the Caribbean.
    Jack N; Ravasi G; Schrooten W; Sutherland D; Ghidinelli M; Del Riego A
    Clin Infect Dis; 2012 May; 54 Suppl 4():S290-3. PubMed ID: 22544189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding the variation in costs among HIV primary care providers.
    Gilman BH; Green JC
    AIDS Care; 2008 Oct; 20(9):1050-6. PubMed ID: 18825514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Scaling up HIV treatment in Peru: applying lessons from DOTS-Plus.
    Sebastian JL; Munoz M; Palacios E; Espiritu B; Mestanza L; Chalco K; Llaro K; Guerra D; Shin S; Bayona J
    J Int Assoc Physicians AIDS Care (Chic); 2006 Dec; 5(4):137-42. PubMed ID: 17101805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.